LUMINY, France, August 1 /PRNewswire-FirstCall/ -- IPSOGEN (Alternext - FR0010626028 - ALIPS), a pioneer and key player in the development and commercialization of molecular diagnostic tests for cancer, today announces its revenue for its first half to 30 June 2008.
For the first half of 2008, revenue totaled EUR1.55 million versus EUR1.09 million for the same period of 2007, an increase of 45.5% at constant forex. At real currency rates, revenue growth was 41.6%.
Sales were up for IPSOGEN’s entire portfolio of leukemia tests, but the JAK2 test recorded the most spectacular growth (+169%) despite the fact that this test only obtained CE certification towards the end of the period.
Vincent Fert, President and CEO, states: “We are very pleased with our achievements over this first half. The growth in activity was buoyant and in line with our expectations. These results confirm the potential of the JAK2 test in the diagnosis of myeloproliferative disorders and show that IPSOGEN’s product portfolio is perfectly positioned to benefit from the molecular diagnosis of cancer market’s very dynamic growth.”
About IPSOGEN
IPSOGEN develops and markets molecular diagnostic assays for patients with cancer. With more than 60 products already used routinely in more than 50 countries for the diagnosis, prognosis and follow-up of thousands of patients with leukemia, IPSOGEN is now also targeting breast cancer with the aim of providing diagnostic information that has been inaccessible until now. IPSOGEN intends to establish itself as a world leader in the molecular diagnosis of cancer. The company is pursuing the development and promotion of diagnostic standards that have a significant impact on patients, medical professionals and society in general. IPSOGEN has a workforce of some 40 people in France and the United States.
Publication of results for the first half of 2008: 9 October 2008 (after market)
CONTACT: Contacts: IPSOGEN, Vincent Fert, President and CEO, Stanislas
Piot, CFO, Tel: +33(0)4-91-29-30-90, investors@ipsogen.com; Bryan, Garnier
& Co. Ltd, Listing Sponsor, Christian Finan, Tel: +33(0)1-56-68-75-20,
cfinan@bryangarnier.com; NewCap., Financial Communication & Investor
Relations, Axelle Vuillermet / Pierre Laurent, Tel: +33(0)1-44-71-94-94,
ipsogen@newcap.fr
